# Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

> **NCT04068831** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Succinate Dehydrogenase Deficient Renal Cell Carcinoma

## Interventions

- **DRUG:** Talazoparib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04068831
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068831, "Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04068831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*